Editor’s note: This round‑up is based on press releases, peer‑reviewed publications, and company communications received in January and February 2026. All results are preliminary unless stated, and ...

McKinnon discusses ‘white space’ in R&D, about integrating generative and agentic AI with human-in-the-loop oversight while prioritising patient safety and regulatory, and how all this advances health ...

An international group of cancer experts has called for fundamental change to healthcare approaches for bile duct cancer, which kills three-quarters of patients within a year of diagnosis.

The advancement of QEL-005 into clinical testing comes shortly after London-headquartered Quell said it was calling a temporary halt to the development of former lead programme QEL-001, designed to ...

The approval gives Ascendis a window of opportunity to eat into BioMarin's market share, as the latter works on its own ...

The Centers for Medicare & Medicaid Services (CMS) in the US has extended the deadline for companies to take part in its ...

Moderna collaborated closely with its global content partner, Wildtype (an Omnicom Health agency), to validate how AI agents fit into real-world workflows. Agencies can serve as a vital testing ground ...

While Global Strategy sets the initial direction, true agility is sustained through a 360-degree loop that prioritises real-time Evidence and Strategy adjustments based on active field signals. To ...

The drug acts as a prostacyclin receptor agonist, which is a fairly crowded class with several approved oral, intravenous, or ...

uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot agree that data from the Phase I/II studies, compared to an external ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings.